SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ringel I,Horwitz SB. Studies with RP 56976: a semisynthetic analogue of Taxol. J Natl Cancer Inst. 1991; 83: 288291.
  • 2
    Bissery MC,Guenard D,Gueritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976, NCS 628503), a Taxol analogue. Cancer Res. 1991; 51: 48454852.
  • 3
    Ganansia-Leymarie V,Bischoff P,Bergerat JP, et al. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents. 2003; 3: 291306.
  • 4
    Valero V,Holmes FA,Walters RS, et al. Phase II trial of docetaxel: a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995; 13: 28862894.
  • 5
    Ravdin PM,Burris HAIII,Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995; 13: 28792885.
  • 6
    Montero A,Fossella F,Hortobagyi G, et al. Docetaxel in solid tumours: a systematic review of the clinical data. Lancet Oncol. 2005; 6: 229239.
  • 7
    Chan S,Friedrichs K,Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.The 303 Study Group. J Clin Oncol. 1999; 17: 23412354.
  • 8
    Nabholtz JM,Senn HJ,Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999; 17: 14131424.
  • 9
    Nabholtz JM,Falkson C,Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003; 21- 968975.
  • 10
    O'Shaughnessy J,Miles D,Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20: 28122823.
  • 11
    Smith IC,Heys SD,Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002; 20: 14561466.
  • 12
    Bear HD,Anderson S,Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003; 21: 41654174.
  • 13
    Roche H,Fumoleau P,Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol. 2006; 24: 56645671.
  • 14
    Martin M,Pienkowski T,Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 23022313.
  • 15
    Hainsworth JD,Burris HA,Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998; 16: 21642168.
  • 16
    Tomiak E,Piccart MJ,Kerger J, et al. Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis. J Clin Oncol. 1994; 12: 14581467.
  • 17
    Burstein HJ,Manola J,Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000; 18: 12121219.
  • 18
    Hainsworth JD,Burris HAIII,Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001; 19: 35003505.
  • 19
    Esteva FJ,Valero V,Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 18001808.
  • 20
    Zubrod CG,Schneiderman M,Frei E, et al. Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thioposphoramide. J Chron Dis. 1960; 11: 733.
  • 21
    Green MC,Buzdar AU,Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 59835992.
  • 22
    Seidman A,Berry D,Cirrincione L, et al. CALGB 9840: Phase II study of weekly paclitaxel via 1-hour infusion versus standard 3 hour infusion every third week in the treatment of metastatic breast cancer with trastuzumab for Her2 positive metastatic breast cancer and randomized for trastuzumab for Her2 positive metastatic breast cancer and randomized for trastuzumab for Her2 normal metastatic breast cancer. J Clin Oncol. 2004; 22: 14s. Abstract 512.
  • 23
    Tabernero J,Climent MA,Lluch A, et al. A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004; 15: 13581365.
  • 24
    Di Maio M,Perrone F,Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2007; 25: 13771382.
  • 25
    Esmaeli B,Amin S,Valero V, et al. Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006; 24: 36193622.
  • 26
    Baker SD,Zhao M,Lee CKK, et al. Comparative pharmacokinetics of weekly and every-3 weeks docetaxel. Clin Cancer Res. 2004; 10: 19761983.
  • 27
    Sparano JA,Wang M,Martino S, et al. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given 3 weeks or weekly in operable breast cancer: results of Intergroup Trial E1199. J Clin Oncol. 2007: 25: 6s. Abstract 516.